+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

CyclinD1, a prominent prognostic marker for endometrial diseases



CyclinD1, a prominent prognostic marker for endometrial diseases



Diagnostic Pathology 8: 138



Alteration of CyclinD1 was suggested to relate with development of endometrial carcinogenesis before, however CyclinD1 expression is not well defined in endometrial hyperplasia lesions. We checked the relationship between its expression and clinic-pathological variables of endometrial lesions to explore the possibility for CyclinD1 as a potential diagnostic and prognostic marker. Cyclin D1 immunohistochemical analysis (IHC) was used to evaluate 201 fixed, paraffin-embedded endometrial samples which included simple hyperplasia (n = 27), atypical complex hyperplasia (ACH) (n = 41), endometrioid carcinoma (n = 103), endometrial serous carcinoma (ESC) (n = 21) and clear cell carcinoma (CCC) (n = 9). A breast cancer with known CyclinD1 expression was selected as a positive control in each immunohistochemistry run. We also performed follow-up study to estimate patients' prognosis. CyclinD1 was significantly overexpressed in atypical complex hyperplasia (ACH), endometrioid carcinoma and clear cell carcinoma (CCC). The positive signaling of CyclinD1 was showed less than 40% in simple hyperplasia and endometrial serous carcinoma (ESC). The high expression of CyclinD1 was observed in metastasis carcinoma group more significantly than non-metastasis carcinoma group. Kaplan Meier analysis demonstrated that patients with high CyclinD1 expression had an obviously poor prognosis than patients without CyclinD1 staining (p < 0.05). Moreover, according to multivariate Cox regression analysis, CyclinD1 expression, as crucial as metastasis, was a risk marker for overall survival rate. CyclinD1 exhibited a promising potential to predict the prognosis of patients with endometrial carcinoma. However, the statistical analysis demonstrated that CyclinD1 exhibited a poor ability to differentiate neoplastic lesions from non-neoplastic lesions; thus, the application of CyclinD1 only is not so credible for differentiation between benign and malignant lesions. The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1871063048950173.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052423006

Download citation: RISBibTeXText

PMID: 23947899

DOI: 10.1186/1746-1596-8-138


Related references

Prognostic significance of cyclinD1 amplification and the co-alteration of cyclinD1/pRb/ppRb in patients with esophageal squamous cell carcinoma. Diseases of the Esophagus 25(7): 664-670, 2013

P53 as a significant prognostic marker in endometrial carcinoma. International Journal of Gynecological Cancer 10(2): 119-127, 2000

HE4 is an independent prognostic marker in endometrial cancer patients. Gynecologic Oncology 126(2): 186-191, 2012

Prognostic significance of CyclinD1 and E-Cadherin in patients with esophageal squamous cell carcinoma: multiinstitutional retrospective analysis. Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Diseases. Journal of the American College of Surgeons 192(6): 708-718, 2001

Lysosomal protease cathepsin D is a prognostic marker in endometrial cancer. British Journal of Cancer 73(12): 1525-1528, 1996

CD24 expression is a poor prognostic marker in endometrial carcinoma. European Journal of Gynaecological Oncology 27(5): 500-504, 2006

LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. International Journal of Gynecological Cancer 20(5): 745-750, 2010

Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma. Cancer Science 97(12): 1308-1314, 2006

S100 as an immunohistochemically-detected marker with prognostic significance in endometrial carcinoma. Anticancer Research 25(3a): 1747-1753, 2005

Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecologic Oncology 63(1): 28-33, 1996

L1CAM as a prognostic marker in stage I endometrial cancer: a validation study. Bmc Cancer 16: 596, 2016

S100 as an immunohistochemically detected marker with prognostic significance in endometrial carcinoma. Anticancer Research 23(6B): 4496-4497, November-December, 2003

Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer 94(11): 2941-2952, 2002

Serum HE4 as a prognostic marker in endometrial cancer--a population based study. Gynecologic Oncology 132(1): 159-165, 2014

Expression of pituitary tumor-transforming gene in endometrial cancer as a prognostic marker. International Journal of Gynecological Cancer 18(6): 1352-1359, 2008